Moderna and Merck prepare to unveil cancer vaccine data at ESMO Congress

Adam Feuerstein reports from the European Society for Medical Oncology meeting in Madrid that the long‑awaited data from the Moderna‑Merck cancer vaccine partnership will be presented in the coming days. The article notes the author’s arrival in Spain and his collaboration with colleague Andrew Joseph to cover the session.

The piece is an exclusive preview for STAT+ subscribers, offering analysis of what investors and clinicians might look for when the results are released. No specific efficacy or safety figures are disclosed, as the data have not yet been made public.

Readers are reminded that the upcoming readout could influence both companies' pipelines and market expectations, but the article itself remains a neutral report on the scheduled presentation.